Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10555937 Pharmaceutical compositions

Patent 10555937 was granted and assigned to Xspray Microparticles AB on February, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 7 Aug, 2024

"update inverses"

Golden AI

edited on 7 Aug, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

Edits on 26 Jun, 2024

"update inverses"

Golden AI

edited on 26 Jun, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 12016861 Amorphous nilotinib microparticles and uses thereof

Edits on 5 Jun, 2024

"update inverses"

Golden AI

edited on 5 Jun, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11998548 Amorphous nilotinib microparticles and uses thereof

Edits on 15 May, 2024

"update inverses"

Golden AI

edited on 15 May, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11980619 Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Edits on 11 Dec, 2023

"Add patent abstract"

Golden AI

edited on 11 Dec, 2023

Edits made to:

Article (+432 characters)

Article

Patent abstract

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Edits on 4 Oct, 2023

"Add patent inventor(s)"

Golden AI

edited on 4 Oct, 2023

Edits made to:

Infobox (+5 properties)

Infobox

Patent Inventor Names

Gérald Jesson0

Helene Dérand0

Magnus Brisander0

Martin Malmsten0

Mustafa Demirbüker0

Edits on 30 Apr, 2023

"update inverses"

Golden AI

edited on 30 Apr, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11633398 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 28 Apr, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 28 Apr, 2023

Infobox

Patent Citations Received

‌

US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 6 Apr, 2023

"Entity importer update"

Golden AI

edited on 6 Apr, 2023

Infobox

Is a

Patent

Patent Applicant

‌

Xspray Microparticles AB

Current Assignee

‌

Xspray Microparticles AB

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

105559370

Date of Patent

February 11, 2020

Patent Application Number

164040270

Date Filed

May 6, 2019

Patent Citations

‌

US Patent 10143683 Pharmaceutical compositions

Patent Citations Received

‌

US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof

‌

US Patent 11324745 Amorphous solid dispersions of dasatinib and uses thereof

‌

US Patent 11389450 Amorphous nilotinib microparticles and uses thereof

‌

US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof

‌

US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Patent Primary Examiner

‌

Jeffrey T. Palenik

Edits on 3 Apr, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 3 Apr, 2023

Infobox

Patent Citations Received

‌

US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 28 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 28 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Edits on 24 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 24 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 11389450 Amorphous nilotinib microparticles and uses thereof

Edits on 25 Jan, 2023

"update inverses"

Golden AI

edited on 25 Jan, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11559485 Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Edits on 26 Sep, 2022

"update citations for inverse infoboxes"

Golden AI

edited on 26 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 11389450 Amorphous nilotinib microparticles and uses thereof

"update citations for inverse infoboxes"

Golden AI

edited on 26 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 17 Aug, 2022

"update inverses"

Golden AI

edited on 17 Aug, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11413290 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 20 Jul, 2022

"update inverses"

Golden AI

edited on 20 Jul, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 11389450 Amorphous nilotinib microparticles and uses thereof

Edits on 19 May, 2022

"update inverses"

Golden AI

edited on 19 May, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 11324745 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 18 May, 2022

"update inverses"

Golden AI

edited on 18 May, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 11298356 Amorphous solid dispersions of dasatinib and uses thereof

Edits on 1 Feb, 2022

"Created via: Entity Importer"

Golden AI

created this topic on 1 Feb, 2022

Edits made to:

Infobox (+10 properties)

‌